drugset / Trial / NCT04803929
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
Phase 0
Unknown
25 enrolled
Carbiogene Therapeutics Co. Ltd.
Zhejiang Provincial People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety and efficacy of novel ILT3-targeted CAR-T cell therapy for patients with relapsed or refractory acute myeloid leukemia (M4/M5).
Timeline
- Start
- 2021-03-03
- Primary completion
- 2024-03-01
- Completion
- 2026-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-ILT3 CAR-T | Cell therapy | — | Intravenous |